ABL90 FLEX PLUS Method Comparison Neonatal Capillary

Radiometer Medical ApS129 enrolled

Overview

The study is intended to validate performance claims for method comparison for ABL90 FLEX PLUS in heparinized neonatal capillary whole blood for ctBil and FHbF in a POC setting

The objective is to perform a method comparison study to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for ctBil and FHbF in heparinized capillary whole blood samples in capillary measuring mode (C65). This study will together with a method comparison study performed with surrogate capillary samples contribute to the overall validation of the performance of ABL90 FLEX for capillary whole blood with regards to the parameters ctBil and FHbF measured using the capillary mode. This study is anticipated to run for approximately 6-12 months from site initiation visit till close-out visit depending on patient enrollment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

129

Conditions

Method Comparison for ABL90 FLEX PLUS in Neonatal Subjects

Interventions

Method ComparisonDEVICE

Quantifying the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for ctBil and FHbF in heparinized capillary whole blood samples in capillary measuring mode (C65).

Eligibility

Sex: ALLMax age: 28 Days

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent collected from legal representative able to understand information given and willing and able to voluntary give their consent to participate in this study. * The age of the subject must be ≤28 days. * Subject evaluated as suitable according to the protocol to enrol in the study by principal investigator or designee Exclusion Criteria: * Subject where sample collection is evaluated by principal investigator or designee to impose an unnecessary risk. * Subject, who has an invalid written informed consent or has withdrawn consent. * Subject who has already provided successful results from capillary samples, to cover both parameters. * Subjects exposed to the substances listed in Appendix 1 with last dose within 72 hours, should be excluded due to risk of interference.

Locations (3)

Albert Einstein College of Medicine

The Bronx, New York, United States

Duke University

Durham, North Carolina, United States

University of Virginia

Charlottesville, Virginia, United States

Outcomes

Primary Outcomes

Primary Endpoints

Bias between device under investigation and comparative device at medical decision level across sites; (unit is mg/dL)

Time frame: 12 months

Secondary Outcomes

Secondary Endpoints

Bias between device under investigation and comparative device at a medical decision point in native capillary samples per site; (unit is mg/dL)

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.